Search

Displaying results 5631 - 5640 of 7498 in total
  1. Drug

    AR-9281

    go.drugbank.com/drugs/DB06345
    Investigational

    AR-9281 inhibits soluble epoxide hydrolase.

  2. Drug

    Iofetamine I-123

    go.drugbank.com/drugs/DB09480
    Approved

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  3. Drug

    Apricitabine

    go.drugbank.com/drugs/DB12855
    Investigational

    Apricitabine has been used in trials studying the treatment of HIV Infections.

  4. Drug

    NV-07a

    go.drugbank.com/drugs/DB05845
    Experimental

    NV-07a is topical skin repair compound protecting skin from sun-induced immunosuppression and UV-induced damage.

  5. Drug

    HY10275

    go.drugbank.com/drugs/DB05079
    Experimental

    HY10275 was rationally designed to "let you sleep" rather than depress the entire brain to "make you sleep." … HY10275 is highly selective for histamine H1 and serotonin 5HT2a, two chemical receptors that are known to impact the ability to fall asleep and stay asleep.

  6. Drug

    Cusatuzumab

    go.drugbank.com/drugs/DB15100
    Investigational

    CD70 is a ligand expressed on the surface of activated lymphocytes and mature dendritic cells that, in its binding to CD27 receptors, plays an important role in cell proliferation and survival.

  7. Drug

    Avdoralimab

    go.drugbank.com/drugs/DB16392
    Investigational

    Avdoralimab is under investigation in clinical trial NCT04333914 (Prospective Study in Patients With Advanced or Metastatic Cancer and Sars-cov-2 Infection).

  8. Drug

    ECT-001 expanded cord blood

    go.drugbank.com/drugs/DB21745
    Investigational

    ECT-001 expanded cord blood is umbilical cord blood (UCB) that has been co-cultured and expanded with the small molecule agonist [UM-171]. … [L52013] It is being investigated in hematopoietic cell transplantation as ECT-001 expanded cord blood can demonstrate enhanced stem cell proliferation and engraftment compared to untreated UBCs.

  9. Drug

    LY2275796

    go.drugbank.com/drugs/DB05165
    Investigational

    LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development. LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that dr...

  10. Drug

    RP01

    go.drugbank.com/drugs/DB05751
    Experimental

    It is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response. … It could offer benefit to millions of asthma and allergy patients.